A. Staehle

Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.

B. Weber, J. Huober, C. Jackisch, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).

C. Jackisch, A. du Bois, A. Burges, 2005, Gynecologic oncology.

Pegylated liposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumors: A phase II trial of the AGO study group.

T. Fehm, A. Reuss, J. Sehouli, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-enrolment of ovarian cancer patients in clinical trials: reasons and background.

C. Schade-Brittinger, J. Huober, P. Harter, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials.

A. Reuss, I. Ray-Coquard, K. Wegscheider, 2013, European journal of cancer.

378 Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor positive endometrial cancer. Protocol AGO-GYN 5, AGO Study Group, Germany

M. Beckmann, J. Sehouli, G. Emons, 2010 .

Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer.

J. Sehouli, P. Dall, G. Emons, 2010 .

Paclitaxel‐carboplatin‐gemcitabine (TCG) as first‐line treatment of ovarian cancer: a prospective multicenter phase II study (AGO‐OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO‐OVAR 9, GINECO‐TCG, NSGO‐OC‐0102) comparing TCG with standard TC

S. Loibl, J. Huober, C. Jackisch, 2005 .